• CD44-Mediated Metabolic Rewiring in IDH-Mutant AML: Therapeu

  2026-05-15

  This study identifies CD44-driven metabolic reprogramming as an essential dependency for IDH-mutant acute myeloid leukemia (AML), enabling sustained oncometabolite production and disease propagation. By elucidating the mechanistic link between CD44 activation, NADPH generation, and resistance to IDH1 inhibition, the research suggests combinatorial targeting strategies to overcome therapeutic limitations in AML.

• Connexin 43/NF-κB Pathway Drives AngII-Induced Macrophage M1

  2026-05-15

  This article reviews a pivotal study demonstrating that angiotensin II (AngII) promotes RAW264.7 macrophage polarization towards a pro-inflammatory M1 phenotype through upregulation of connexin 43 (Cx43) and subsequent activation of the NF-κB (p65) pathway. The findings clarify the mechanistic role of Cx43-mediated gap junction signaling in immune modulation, with implications for targeted experimental intervention in inflammation and cardiovascular research.

• WAY-100635: Transforming 5-HT1A Receptor Antagonist Research

  2026-05-14

  Explore the profound role of WAY-100635 in advancing serotonin receptor antagonist research, with new insights into its mechanisms, applications, and the strategic impact of recent findings on assay design. Discover expert protocols and a critical analysis distinct from existing resources.

• Collagen VI-Enhanced ECM Scaffolds Advance iPSC Islet Organo

  2026-05-14

  This study demonstrates that decellularized amniotic membrane (dAM) hydrogels enriched with collagen VI significantly improve the viability and functional maturity of iPSC-derived islet organoids. The findings offer a promising biomimetic platform for diabetes cell therapy, with implications for optimizing extracellular matrix composition in organoid engineering.

• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Research Applicat

  2026-05-13

  Digoxin’s dual role as a Na+/K+ ATPase pump inhibitor unlocks validated protocols for both cardiac and antiviral research. This article translates bench-level evidence into actionable workflows, with troubleshooting and optimization tips for maximizing reproducibility in both cardiovascular and virology models.

• Cyclosporin A: Optimizing Immunosuppression & Mitochondrial

  2026-05-13

  Cyclosporin A stands at the crossroads of immunology and mitochondrial research, enabling precise inhibition of T-cell activation and mitochondrial permeability transition pore dynamics. This article demystifies experimental protocols, highlights a key innovation in cyclophilin targeting, and delivers actionable troubleshooting strategies for reproducible, high-impact results.

• Biotin-tyramide: Practical Guide for Signal Amplification Wo

  2026-05-12

  Biotin-tyramide (A8011) is a biotin phenol reagent optimized for tyramide signal amplification (TSA) in immunohistochemistry (IHC) and in situ hybridization (ISH). It addresses the need for high-resolution, enzyme-mediated signal amplification, but should not be used in diagnostic or live-cell contexts outside established protocols. Its use is restricted to fixed samples and research workflows that require precise biotin labeling and subsequent streptavidin detection.

• Go 6983 Pan-PKC Inhibitor: Applied Workflows for Cell Fate R

  2026-05-12

  Go 6983 (pan-PKC inhibitor) empowers researchers to dissect PKC-dependent mechanisms in cancer progression and early embryonic lineage commitment. This guide translates cutting-edge findings and best practices into actionable protocols, troubleshooting tips, and comparative insights for robust PKC signaling pathway research.

• Lipo3K Transfection Reagent: Unraveling Mechanisms and Innov

  2026-05-11

  Explore how Lipo3K Transfection Reagent enables high-efficiency gene delivery, with a scientific deep dive into its mechanism and unique relevance to kidney organoid assays. This article goes beyond protocol optimization to bridge molecular insights and practical workflow advances.

• Targeting Metabolic Dependencies in IDH1-Mutant AML with AG-

  2026-05-11

  This thought-leadership article examines how AG-120 (Ivosidenib) enables translational researchers to target metabolic rewiring and differentiation blockade in IDH1-mutant acute myeloid leukemia (AML). Integrating mechanistic insight from recent CD44-mediated metabolic studies and practical workflow guidance, the piece highlights strategic considerations for deploying AG-120 in advanced AML research and clinical translation.

• CD44-Driven Metabolic Rewiring in IDH1-Mutant Leukemia

  2026-05-10

  This study elucidates how CD44 upregulation in IDH-mutant leukemia drives pentose phosphate pathway activation to sustain NADPH and R-2HG production, uncovering a targetable metabolic dependency. The findings suggest that combinatorial targeting of CD44 and mutant IDH1 could address therapeutic resistance and improve outcomes in AML.

• Annexin V-FITC/PI Apoptosis Assay Kit: Technical Protocol Gu

  2026-05-09

  The Annexin V-FITC/PI Apoptosis Assay Kit enables rapid, reliable discrimination of viable, early apoptotic, and late apoptotic or necrotic cells in cell populations. It is most suitable for research workflows requiring fluorescence-based apoptosis detection via flow cytometry or microscopy, but is not intended for diagnostic or clinical use. Users should not extrapolate its utility to tissue sections or non-cellular systems.

• SAR405 (SKU A8883): Reliable Vps34 Inhibitor for Autophagy R

  2026-05-08

  This article addresses common laboratory challenges in autophagy, vesicle trafficking, and lysosome function assays, demonstrating how SAR405 (SKU A8883) delivers reproducible, selective Vps34 inhibition. Scenario-driven Q&A contrasts SAR405’s nano-molar potency, workflow compatibility, and vendor reliability, offering actionable guidance for biomedical researchers.

• Angiotensin II in AAA Pathogenesis: Mechanistic and Translat

  2026-05-08

  Explore how Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) models abdominal aortic aneurysm (AAA) development, integrating new cross-omics evidence and advanced assay parameters. This article delivers a deeper, mechanistically grounded resource for vascular disease research.

• L-Alanyl-L-Glutamine (B8228): Technical Guide for GI Barrier

  2026-05-07

  L-Alanyl-L-Glutamine (L-Ala-L-Gln dipeptide) provides a stable, water-soluble supplement for enhancing intestinal barrier function and mucosal protection in gastrointestinal research workflows. It is best suited for controlled in vitro and in vivo assays where solubility, purity, and reproducibility are critical. Use outside gastrointestinal or nutritional model systems is not recommended.

464 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page